Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Universal Health (UHS) Q3 Earnings Miss Mark, Decline Y/Y

Published 10/26/2021, 01:11 AM
Updated 07/09/2023, 06:31 AM
AAPL
-
THC
-
HCA
-
UHS
-

Universal Health (NYSE:UHS) Services, Inc. UHS reported third-quarter 2021 adjusted earnings of $2.67 per share, which missed the Zacks Consensus Estimate by 4.3%. The bottom line decreased 7.3% year over year.

Results were hurt by escalating expenses and a weak performance by its Behavioral Health Care Services segment.

While adjusted admissions on same facility basis at the company’s Acute Care Hospital Services segment climbed 12.4% year over year in the third quarter, the same for Behavioral Health Care Services segment dipped 2.7% year over year.

Quarterly Operational Update

Net revenues of $3.2 billion improved 8.3% year over year. The top line met the consensus mark.

Total operating costs rose 10.9% year over year to $2.8 billion in the second quarter, mainly due to increased salaries, wages and benefits, other operating expenses, supplies expense, depreciation and amortization.

Segmental Update

Acute Care Hospital Services

On same facility basis, adjusted patient days increased 10.9% year over year in the third quarter. Net revenues improved 13.1% year over year in the quarter on same facility basis from the company’s acute care services.

Behavioral Health Care Services

In the quarter under review, adjusted patient days on same facility basis slid 2.1% year over year. Net revenues drawn from the company’s behavioral health care services inched up 2% year over year.

Financial Update (as of Sep 30, 2021)

Universal Health exited the third quarter with cash and cash equivalents of $190 million, down 84.5% from the level at 2020 end.

The company had no borrowings outstanding and $1.196 billion of available borrowing capacity, net of outstanding letters of credit.

Total assets of $12.8 billion fell 4.7% from the figure as of Dec 31, 2020.

The company’s long-term debt totaled $3.7 billion, which increased 5.3% from the 2020-end level.

During the first nine months of 2021, net cash provided by operating activities of $562 million plunged 74.7% from the year-ago comparable period’s figure.
This was mainly due to an unfavorable change stemming from the repayments of Medicare accelerated payments, unfavorable change in accounts receivable and accrued and deferred income taxes, etc.

Share Repurchase Update

In the third quarter, the company bought back 2.78 million shares worth $419.1 million.

As of Sep 30, 2021, the company had an aggregate stock buyback plan of $3.7 billion, which was originally approved by its board of directors in various increments since 2014.

Zacks Rank

Universal Health currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Other Medical Sector Releases

Of the medical sector players that have reported second-quarter results so far, the bottom-line results of Tenet Healthcare Corporation (NYSE:THC) THC, HCA Healthcare (NYSE:HCA), Inc. HCA and Anthem, Inc. ANTM beat the Zacks Consensus Estimate.


More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.

Click here for the 4 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Universal Health Services, Inc. (UHS): Free Stock Analysis Report

Tenet Healthcare Corporation (THC): Free Stock Analysis Report

HCA Healthcare, Inc. (HCA): Free Stock Analysis Report

Anthem, Inc. (ANTM): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.